Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Travere Therapeutics, Inc. | CHIEF COMMERCIAL OFFICER | Common Stock | 108K | $1.24M | $11.52 | Sep 9, 2024 | Direct |
Travere Therapeutics, Inc. | CHIEF COMMERCIAL OFFICER | Employee stock option (right to buy) | 65K | Jan 31, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
TVTX | Travere Therapeutics, Inc. | Sep 5, 2024 | 2 | -$25.2K | 4 | Sep 9, 2024 | CHIEF COMMERCIAL OFFICER |
TVTX | Travere Therapeutics, Inc. | Jan 31, 2024 | 3 | -$35.8K | 4 | Feb 2, 2024 | CHIEF COMMERCIAL OFFICER |
TVTX | Travere Therapeutics, Inc. | Jan 23, 2024 | 1 | -$14.1K | 4 | Jan 25, 2024 | CHIEF COMMERCIAL OFFICER |
TVTX | Travere Therapeutics, Inc. | Oct 3, 2023 | 1 | -$25.5K | 4 | Oct 4, 2023 | Chief Commercial Officer |
TVTX | Travere Therapeutics, Inc. | Jan 31, 2023 | 4 | -$38.7K | 4 | Feb 2, 2023 | Chief Commercial Officer |
TVTX | Travere Therapeutics, Inc. | Jan 24, 2023 | 1 | -$34K | 4 | Jan 26, 2023 | Chief Commercial Officer |
TVTX | Travere Therapeutics, Inc. | Oct 4, 2022 | 1 | -$78.1K | 4 | Oct 6, 2022 | Chief Commercial Officer |
TVTX | Travere Therapeutics, Inc. | Jan 31, 2022 | 5 | -$30.8K | 4 | Feb 2, 2022 | Chief Commercial Officer |
TVTX | Travere Therapeutics, Inc. | Jan 24, 2022 | 1 | -$46.8K | 4 | Jan 26, 2022 | Chief Commercial Officer |
TVTX | Travere Therapeutics, Inc. | Oct 4, 2021 | 1 | -$75.7K | 4 | Oct 5, 2021 | Chief Commercial Officer |
TVTX | Travere Therapeutics, Inc. | Aug 13, 2021 | 2 | -$24.1K | 4 | Aug 17, 2021 | Chief Commercial Officer |